1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Contraceptive Drugs Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Product
6.1 Oral Contraceptive Pills
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Injectable Contraceptives
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Topical Contraceptives
6.3.1 Market Trends
6.3.2 Market Forecast
7 Market Breakup by Age Group
7.1 15–24 years
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 25–34 years
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 35–44 years
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Above 44 years
7.4.1 Market Trends
7.4.2 Market Forecast
8 Market Breakup by Distribution Channel
8.1 Retail Pharmacy
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Hospital Pharmacy
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Clinics
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Online Channel
8.4.1 Market Trends
8.4.2 Market Forecast
8.5 Public Channel and NGOs
8.5.1 Market Trends
8.5.2 Market Forecast
8.6 Others
8.6.1 Market Trends
8.6.2 Market Forecast
9 Market Breakup by Region
9.1 North America
9.1.1 United States
9.1.1.1 Market Trends
9.1.1.2 Market Forecast
9.1.2 Canada
9.1.2.1 Market Trends
9.1.2.2 Market Forecast
9.2 Asia-Pacific
9.2.1 China
9.2.1.1 Market Trends
9.2.1.2 Market Forecast
9.2.2 Japan
9.2.2.1 Market Trends
9.2.2.2 Market Forecast
9.2.3 India
9.2.3.1 Market Trends
9.2.3.2 Market Forecast
9.2.4 South Korea
9.2.4.1 Market Trends
9.2.4.2 Market Forecast
9.2.5 Australia
9.2.5.1 Market Trends
9.2.5.2 Market Forecast
9.2.6 Indonesia
9.2.6.1 Market Trends
9.2.6.2 Market Forecast
9.2.7 Others
9.2.7.1 Market Trends
9.2.7.2 Market Forecast
9.3 Europe
9.3.1 Germany
9.3.1.1 Market Trends
9.3.1.2 Market Forecast
9.3.2 France
9.3.2.1 Market Trends
9.3.2.2 Market Forecast
9.3.3 United Kingdom
9.3.3.1 Market Trends
9.3.3.2 Market Forecast
9.3.4 Italy
9.3.4.1 Market Trends
9.3.4.2 Market Forecast
9.3.5 Spain
9.3.5.1 Market Trends
9.3.5.2 Market Forecast
9.3.6 Russia
9.3.6.1 Market Trends
9.3.6.2 Market Forecast
9.3.7 Others
9.3.7.1 Market Trends
9.3.7.2 Market Forecast
9.4 Latin America
9.4.1 Brazil
9.4.1.1 Market Trends
9.4.1.2 Market Forecast
9.4.2 Mexico
9.4.2.1 Market Trends
9.4.2.2 Market Forecast
9.4.3 Others
9.4.3.1 Market Trends
9.4.3.2 Market Forecast
9.5 Middle East and Africa
9.5.1 Market Trends
9.5.2 Market Breakup by Country
9.5.3 Market Forecast
10 SWOT Analysis
10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 AbbVie Inc.
14.3.1.1 Company Overview
14.3.1.2 Product Portfolio
14.3.1.3 Financials
14.3.1.4 SWOT Analysis
14.3.2 Afaxys Inc.
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.3 Agile Therapeutics
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.3.3 Financials
14.3.4 Amneal Pharmaceuticals Inc.
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.4.3 Financials
14.3.5 Bayer AG
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio
14.3.5.3 Financials
14.3.5.4 SWOT Analysis
14.3.6 Johnson & Johnson
14.3.6.1 Company Overview
14.3.6.2 Product Portfolio
14.3.6.3 Financials
14.3.6.4 SWOT Analysis
14.3.7 Mithra Pharmaceuticals SA
14.3.7.1 Company Overview
14.3.7.2 Product Portfolio
14.3.7.3 Financials
14.3.8 Novartis AG
14.3.8.1 Company Overview
14.3.8.2 Product Portfolio
14.3.8.3 Financials
14.3.8.4 SWOT Analysis
14.3.9 Pfizer Inc.
14.3.9.1 Company Overview
14.3.9.2 Product Portfolio
14.3.9.3 Financials
14.3.9.4 SWOT Analysis
14.3.10 Teva Pharmaceutical Industries Ltd.
14.3.10.1 Company Overview
14.3.10.2 Product Portfolio
14.3.10.3 Financials
14.3.10.4 SWOT Analysis
14.3.11 Viatris Inc.
14.3.11.1 Company Overview
14.3.11.2 Product Portfolio
14.3.11.3 Financials
世界の避妊薬市場予測2023年-2028年 |
| 【英語タイトル】Contraceptive Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028 | |
 | ・商品コード：IMARC23AP145 ・発行会社（調査会社）：IMARC ・発行日：2023年3月2日 ・ページ数：143 ・レポート言語：英語 ・レポート形式：PDF ・納品方法：Eメール ・調査対象地域：グローバル ・産業分野：医薬品 |
| Single User | USD2,999 ⇒換算￥449,850 | 見積依頼/購入/質問フォーム |
| Five User | USD3,999 ⇒換算￥599,850 | 見積依頼/購入/質問フォーム |
| Enterprisewide | USD4,999 ⇒換算￥749,850 | 見積依頼/購入/質問フォーム |
|
※販売価格オプションの説明 ※お支払金額：換算金額（日本円）＋消費税 ※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡） ※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能） |
| IMARC社の本調査レポートでは、2022年に150億ドルであった世界の避妊薬市場規模が、2028年までに208億ドルに拡大し、予測期間中にCAGR5.4%で成長すると予想しています。本書は、避妊薬の世界市場を調査・分析し、序論、範囲・調査手法、エグゼクティブサマリー、イントロダクション、製品別（経口避妊薬、避妊注射剤、外用避妊薬）分析、年齢層別（15～24歳、25～34歳、35～44歳、44歳以上）分析、流通チャネル別（小売薬局、病院薬局、クリニック、オンライン、その他）分析、地域別（北米、アジア太平洋、ヨーロッパ、中南米、中東・アフリカ）分析、SWOT分析、バリューチェーン分析、ポーターズファイブフォース分析、価格分析、競争状況などの項目を整理しています。また、本書には、AbbVie Inc.、Afaxys Inc.、Agile Therapeutics、Amneal Pharmaceuticals Inc.、Bayer AG、Johnson & Johnson、Mithra Pharmaceuticals SA、Novartis AG、Pfizer Inc.、Teva Pharmaceutical Industries Ltd. and Viatris Inc.などの企業情報が含まれています。 ・序論 ・範囲・調査手法 ・エグゼクティブサマリー ・イントロダクション ・世界の避妊薬市場規模：製品別 - 経口避妊薬の市場規模 - 避妊注射剤の市場規模 - 外用避妊薬の市場規模 ・世界の避妊薬市場規模：年齢層別 - 15～24歳における市場規模 - 25～34歳における市場規模 - 35～44歳における市場規模 - 44歳以上における市場規模 ・世界の避妊薬市場規模：流通チャネル別 - 小売薬局チャネルの市場規模 - 病院薬局チャネルの市場規模 - クリニックチャネルの市場規模 - オンラインチャネルの市場規模 - その他の市場規模 ・世界の避妊薬市場規模：地域別 - 北米の避妊薬市場規模 - アジア太平洋の避妊薬市場規模 - ヨーロッパの避妊薬市場規模 - 中南米の避妊薬市場規模 - 中東・アフリカの避妊薬市場規模 ・SWOT分析 ・バリューチェーン分析 ・ポーターズファイブフォース分析 ・価格分析 ・競争状況 |
Market Overview:
The global contraceptive drugs market size reached US$ 15.0 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 20.8 Billion by 2028, exhibiting a growth rate (CAGR) of 5.4% during 2023-2028.
Contraceptive drugs refer to birth control medications that are used to prevent pregnancy and control the birth rate. They are synthetically formulated using two female hormones, namely estrogen and progestin, which prevent ovulation. These hormones also thicken cervical mucus or alter the womb lining to prohibit the entrance of sperm into the cervix for fertilization and implantation. Contraceptive drugs assist in lowering the risks of acne, bone thinning, ovarian cancer, infections in the fallopian tubes and uterus, and premenstrual syndrome (PMS). As a result, they are administered by healthcare practitioners to inhibit unwanted pregnancy amongst women of childbearing age. At present, they are mainly available in oral, injectable, and topical formulations.
Contraceptive Drugs Market Trends:
One of the key factors driving the global contraceptive drugs market is the rising consumer consciousness regarding family planning, the increasing population, and the rising instances of unintended pregnancies. In line with this, the shifting inclination of healthcare practitioners toward modern contraceptive methods over conventional procedures, owing to their multiple benefits, including optimal safety, and better clinical outcomes, are acting as another growth-inducing factor. Additionally, the frequent approvals of novel medications by several regulatory bodies, such as the food and drug administration (FDA), are supporting the market growth. Moreover, the advent of gelatin capsules and non-hormonal vaginal gels that create an inhospitable environment for sperm to sustain by maintaining vagina pH levels is impelling the market growth. Apart from this, continuous research and development (R&D) activities and the favorable initiatives undertaken by non-governmental organizations (NGOs) and health agencies to sensitize consumers about contraception techniques, womens health, and sexual wellness are positively augmenting the market growth.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global contraceptive drugs market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on product, age group and distribution channel.
Breakup by Product:
Oral Contraceptive Pills
Injectable Contraceptives
Topical Contraceptives
Breakup by Age Group:
15–24 years
25–34 years
35–44 years
Above 44 years
Breakup by Distribution Channel:
Retail Pharmacy
Hospital Pharmacy
Clinics
Online Channel
Public Channel and NGOs
Others
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being AbbVie Inc., Afaxys Inc., Agile Therapeutics, Amneal Pharmaceuticals Inc., Bayer AG, Johnson & Johnson, Mithra Pharmaceuticals SA, Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd. and Viatris Inc.
Key Questions Answered in This Report:
How has the global contraceptive drugs market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global contraceptive drugs market?
What are the key regional markets?
What is the breakup of the market based on the product?
What is the breakup of the market based on the age group?
What is the breakup of the market based on the distribution channel?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global contraceptive drugs market and who are the key players?
What is the degree of competition in the industry?
❖ レポートの目次 ❖
| ★調査レポート[世界の避妊薬市場予測2023年-2028年] (コード：IMARC23AP145)販売に関する免責事項を必ずご確認ください。 |
| ★調査レポート[世界の避妊薬市場予測2023年-2028年]についてメールでお問い合わせ |
